Mounjaro®
Starting from £179.99/mo
Start journey Learn moreItchy skin is not listed among the common side effects of Mounjaro, but it can occur, typically as part of an injection-site reaction or, less often, as a sign of an allergic response. Mounjaro (tirzepatide) is a prescription-only medicine requiring clinical assessment before it is prescribed. Most skin reactions are mild and resolve on their own, but some need prompt medical attention — and knowing the difference matters. Our prescribers at nume talk through side effects, including skin reactions, as a routine part of every consultation.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Yes, and it is far more common than a generalised body itch. When you inject tirzepatide into the abdomen, thigh or upper arm, the surrounding tissue can respond with redness, mild swelling, a small lump or itching — usually within a few hours and settling within a day or two. The NHS patient information for tirzepatide lists injection-site reactions as a common side effect, meaning they affect roughly one in ten people or more. A cold compress held gently against the spot for a few minutes after injecting can reduce the immediate sting. Rotating sites (abdomen, thigh, upper arm in turn) also prevents the same patch of skin from being irritated repeatedly. If the redness spreads well beyond the injection spot, feels hot to the touch or does not fade after a couple of days, that is worth flagging to your prescriber rather than managing at home. For a broader overview of what Mounjaro side effects tend to look like across the body, see our Mounjaro side effects guide.
It can. Some people report a more diffuse itch (no rash, no obvious cause) that seems to coincide with starting tirzepatide or moving up a dose. The precise mechanism is not fully understood, but it may relate to changes in bile acid metabolism as the medicine slows gastric emptying, or to the immune system's response to a new subcutaneous medicine. This kind of itch tends to be mild and often settles within a few days as the body adjusts. If you want to understand whether itching is a recognised side effect of Mounjaro, including how commonly it occurs and what typically triggers it, our dedicated page goes into detail. Skin changes that are harder to explain (persistent itch, a new rash, yellowing of the skin or eyes) should always prompt a call to your GP or prescriber. Yellowing in particular can indicate a liver or gallbladder issue, which GLP-1 medicines can occasionally affect.
Some skin reactions are a signal to get help the same day rather than wait. Seek urgent medical attention if you develop hives (raised, blotchy welts) across your chest, face or limbs, especially alongside swelling of the lips, tongue or throat, difficulty breathing, or a sudden drop in blood pressure. These can be signs of a serious allergic reaction (anaphylaxis), rare with tirzepatide but documented in post-marketing surveillance. Stop the injection and call 999 or go to A&E. A reaction that is clearly worsening within minutes needs emergency services, not a pharmacist's advice line. For reactions that are uncomfortable but not severe (widespread itching without throat involvement, a persistent rash) contact your prescriber or GP the same day. If you are unsure what to look out for, our page on the side effect of Mounjaro gives a clear rundown of what has been reported and when each type warrants attention. The MHRA's Yellow Card scheme is there for patients to report any suspected side effect, including skin reactions, and your report genuinely contributes to the safety monitoring of newer medicines like tirzepatide. Tirzepatide still carries a Black Triangle (▼) status, which means the MHRA is actively collecting and reviewing safety data, your report counts. You can also read about whether Mounjaro side effects improve over time, since many do ease after the first few weeks.
Not necessarily. A mild, transient itch at the injection site is a common enough experience that it rarely leads to stopping treatment, and it typically resolves once the body has adapted to the medicine. A genuine allergic reaction is different, if that is confirmed by your prescriber, continuing tirzepatide is not appropriate. The decision always rests on a clinical assessment of the reaction's nature and severity. Mounjaro side effects linked to skin are one piece of a broader picture that our prescribers consider when reviewing suitability, alongside your full medical history. If you are curious about other skin-related changes people notice on tirzepatide, including hair changes sometimes reported during significant weight loss, the page on hair loss as a Mounjaro side effect covers the evidence. For a deeper look at what is known specifically about Mounjaro and the skin, our skin side effects page covers the topic fully. If you want to discuss whether tirzepatide is clinically suitable for you, including how side effects like these would be monitored, checking your eligibility with our prescribers is the straightforward next step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.